Bad to the Bone
Jennifer L. Crombie(Dana-Farber Cancer Institute), David C. Fisher(Dana-Farber Cancer Institute), Annette S. Kim, Anand Jayprakash Vaidya(San Jose State University), Ramkumar Venkateswaran
Cited by 0
Related Papers
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
|The Lancet|2017|580
Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma
|Journal of Clinical Oncology|2017|468
The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice
|Cancer Cell|2016|304